Lentinan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lentinan
Accession Number
DB13480
Type
Small Molecule
Groups
Experimental, Investigational
Description
Not Available
Synonyms
Not Available
External IDs
LC 33 / LC-33
Categories
UNII
6751655D1D
CAS number
37339-90-5
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Lentinan.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Lentinan.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Lentinan.Approved, Investigational, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Lentinan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lentinan.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Lentinan.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Lentinan.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Lentinan.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Lentinan.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Lentinan.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lentinan.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lentinan.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Lentinan.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Lentinan.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Lentinan.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Lentinan.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Lentinan.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lentinan.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Lentinan.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Lentinan.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Lentinan.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Lentinan
ATC Codes
L03AX01 — Lentinan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on June 23, 2017 14:42 / Updated on July 02, 2018 19:51